- Sales grow by 35.0% to CHF 239.1 million.
- EBITDA rises from CHF 53.0 million to CHF 75.5 million and a margin of 31.6%.
- Operating income (EBIT) increases from CHF 40.3 million to CHF 61.9 million and a margin of 25.9%.
- Net income rises from CHF 32.8 million to CHF 53.1 million and a margin of 22.2%.
- Investments of over CHF 50 million and creation of 107 new jobs (77 of which are in Switzerland) since the beginning of the year.
The first half of 2021 has gone very well for Bachem. I am particularly pleased that we have been able to grow both our business, as well as our capacity and workforce simultaneously. Bachem is definitely on track to reach its company goals and continue to grow sustainably and profitably in the coming years.
CEO
The Bachem Group (SIX: BANB) increased its sales during the first half of 2021 in Swiss francs by 35.0% to CHF 239.1 million. Operating income before
depreciation and amortization (EBITDA) rose by 42.5% to CHF 75.5 million and operating income (EBIT) grew by 53.9% to CHF 61.9 million. This results in an EBITDA margin of 31.6% (first half-year 2020: 29.9%) and an EBIT margin of 25.9% (first half-year 2020: 22.7%). Net income increased by 61.8% to CHF 53.1 million and a margin of 22.2% (first half-year 2020: 18.5%).
- Sales of CHF 500 million are now expected for the year 2021.
- Bachem expects an average annual rate of growth of about 15% for the coming five years.
- Bachem intends to grow operating income (EBIT) at a rate ahead of sales.
- The company is now planning investments over CHF 500 million for the next five years across sites and business areas in order to further expand capacity.
The complete half-year report 2021, including the slides for the analyst- and media conference can be downloaded in the reports and presentations section of our homepage.
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides.
With 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.
-
Name*First NameLast Name
- Job Title
- Company Name
- Business unit/Dept.
- Email Address*
-
Address*Street AddressCityStateZIP / Postal CodeCountryAfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongo, Democratic Republic of theCongo, Republic of theCook IslandsCosta RicaCroatiaCubaCuraçaoCyprusCzech RepublicCôte d'IvoireDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatini (Swaziland)EthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard and McDonald IslandsHoly SeeHondurasHong KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacauMacedoniaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth KoreaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestine, State ofPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarRomaniaRussiaRwandaRéunionSaint BarthélemySaint HelenaSaint Kitts and NevisSaint LuciaSaint MartinSaint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth GeorgiaSouth KoreaSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan Mayen IslandsSwedenSwitzerlandSyriaTaiwanTajikistanTanzaniaThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTurks and Caicos IslandsTuvaluUS Minor Outlying IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuelaVietnamVirgin Islands, BritishVirgin Islands, U.S.Wallis and FutunaWestern SaharaYemenZambiaZimbabweÅland Islands
- Phone / Mobile
-
What can we help you with?
Please selectOrder an annual reportAsk a question / request information
- Comments
Please choose if you would like to receive additional email communications from Bachem:
-
Sign up for newsletter
- Sign up for newsletter
Fields marked with an asterisk (*) are required
- HiddenSubmission Time:HoursMinutes
- HiddenRefer Url.
-
Name
This field is for validation purposes and should be left unchanged.
Bachem Holding AG
Dr. Daniel Grotzky
Head Group Communications
Media:media[at]bachem.com
Investors:ir[at]bachem.com
Attachments
- Original document
- Permalink
Disclaimer
Bachem Holding AG published this content on 27 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 August 2021 04:50:03 UTC.